Search Result

Isoforms Recommended:	HDAC6

Results for "

HDAC6

" in MCE Product Catalog:

By Targets:	Akt (1) Amyloid-β (2) Apoptosis (40) Autophagy (6) Caspase (2) CDK (2) Cholinesterase (ChE) (2) FGFR (1) Filovirus (1) Guanylate Cyclase (1) HDAC (108) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (2) HIV (1) HPV (1) HSP (2) iGluR (1) JAK (1) MDM-2/p53 (1) Microtubule/Tubulin (2) Mitophagy (1) mTOR (2) Parasite (2) PARP (1) PI3K (1) Pim (1) PROTACs (3) Proteasome (1) Reactive Oxygen Species (1) Topoisomerase (2) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (96) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (7) Neurological Disease (11)

By Targets:

Akt (1)

Amyloid-β (2)

Apoptosis (40)

Autophagy (6)

Caspase (2)

CDK (2)

Cholinesterase (ChE) (2)

FGFR (1)

Filovirus (1)

Guanylate Cyclase (1)

HDAC (108)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (2)

HIV (1)

HPV (1)

HSP (2)

iGluR (1)

JAK (1)

MDM-2/p53 (1)

Microtubule/Tubulin (2)

Mitophagy (1)

mTOR (2)

Parasite (2)

PARP (1)

PI3K (1)

Pim (1)

PROTACs (3)

Proteasome (1)

Reactive Oxygen Species (1)

Topoisomerase (2)

VEGFR (1)

Virus Protease (1)

By Research Areas:

Cancer (96)

Cardiovascular Disease (3)

Infection (5)

Inflammation/Immunology (7)

Neurological Disease (11)

111

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas

HY-132998

HDAC6 degrader-1	PROTACs	Others
HDAC6 degrader-1 is a PROTAC that comprises a selective HDAC6 inhibitor Nexturastat A (Nex A) as the HDAC6 binder, a linker and a ligand for recruiting E3 ligase. HDAC6 degrader-1 induces significant degradation of HDAC6, exhibits excellent selectivity against other HDACs, and demonstrates efficient inhibition of cell proliferation.

HY-152134

HDAC6 degrader-3	HDAC PROTACs	Cancer
HDAC6 degrader-3 is a potent and selective *HDAC6* degrader via ternary complex formation and the ubiquitin-proteasome pathway with a DC₅₀ value of 19.4 nM. HDAC6 degrader-3 has IC₅₀s of 4.54 nM and 0.647 μM for HDAC6 and HDAC1, respectively. HDAC6 degrader-3 causes strong hyperacetylation of α-tubulin.

HY-130493

HPB
HDAC6 inhibitor HPB
HDAC Cancer

HPB (HDAC6 inhibitor HPB) is a selective HDAC6 inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1.

HPB HDAC6 inhibitor HPB	HDAC	Cancer
HPB (HDAC6 inhibitor HPB) is a selective *HDAC6* inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1.

HY-150722

HDAC6-IN-12	HDAC	Cancer
HDAC6-IN-12 (compound GZ) is a potent *HDAC6* inhibitor. HDAC6-IN-12 has anticancer activity through merges into DNA strands causing DNA damage. HDAC6-IN-12 can be used for cancer research.

HY-107550

HDAC6-IN-7
HDAC Cancer

TCS HDAC6 20b is a HDAC6-selective inhibitor. TCS HDAC6 20b blocks the growth of estrogen receptor α-positive breast cancer MCF-7 cells.
HY-151896

HDAC6-IN-14
HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4.

HDAC6-IN-7	HDAC	Cancer
TCS HDAC6 20b is a *HDAC6*-selective inhibitor. TCS HDAC6 20b blocks the growth of estrogen receptor α-positive breast cancer MCF-7 cells.

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4.

HY-145259

HDAC6-IN-3	HDAC Histone Demethylase	Cancer
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active *HDAC6* inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor.

HY-152235

HDAC6-IN-15	HDAC	Cancer Neurological Disease
HDAC6-IN-15 is a selective histone deacetylase 6 (HDAC6) inhibitor. HDAC6-IN-15 has potent inhibitory activity for HDAC6 with IC₅₀ value of 38.2 nM. HDAC6-IN-15 can be used for the research of cancer and neurodegenerative diseases.

HY-151364

HDAC6/8/BRPF1-IN-1	HDAC	Cancer
HDAC6/8/BRPF1-IN-1 is a dual inhibitor of both HDAC6/8 and the bromodomain and PHD finger containing protein 1 (BRPF1). HDAC6/8/BRPF1-IN-1 has inhibitory activity for HDAC1, HDAC6 and HDAC8 with IC₅₀ values of 797 nM, 344 nM and 908 nM, respectively. HDAC6/8/BRPF1-IN-1 has inhibitory activity for BRPF1 with an K_d value of 175.2 nM. HDAC6/8/BRPF1-IN-1 can be used for the research of cancer.

HY-150595

HDAC6-IN-10	HDAC Microtubule/Tubulin	Cancer
HDAC6-IN-10 is a highly selective *HDAC6* inhibitor with the IC₅₀ of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells.

HY-150694

HDAC6-IN-11	HDAC	Cancer
HDAC6-IN-11 (Compound 9) is a selective *HDAC6* inhibitor with the IC₅₀ value of 20.7 nM. HDAC6-IN-11 has more than 300-fold selectivity over HDAC other isoforms. HDAC6-IN-11 shows anti-proliferative activities against cancer cells.

HY-144395

HDAC6-IN-4	HDAC Apoptosis	Cancer Inflammation/Immunology
HDAC6-IN-4 (C10) is a potent, orally active and highly selective *HDAC6* inhibitor with an IC₅₀ value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity.

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective *HDAC6* inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities.

HY-146678

HDAC6-IN-5	HDAC Amyloid-β Cholinesterase (ChE)	Neurological Disease
HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated *HDAC6* inhibitor, with an IC₅₀ of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ_1-42 self-aggregation and AChE, with IC₅₀ values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity.

HY-151261

HDAC6-IN-13	HDAC	Inflammation/Immunology
HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active *HDAC6* inhibitor with an IC₅₀ of 0.019 μM. HDAC6-IN-13 also inhibits *HDAC1, HDAC2* and *HDAC3* with IC₅₀s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity.

HY-146679

HDAC6-IN-6	HDAC Amyloid-β Cholinesterase (ChE)	Neurological Disease
HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated *HDAC6* inhibitor, with an IC₅₀ of 0.025 μM. HDAC6-IN-6 exhibits strong inhibitory activity against Aβ_1-42 self-aggregation and AChE, with IC₅₀ values of 3.0 and 0.72 μM. HDAC6-IN-6 can enhance neurite outgrowth without significant neurotoxicity.

HY-150774

HDAC6/HSP90-IN-2	HDAC HSP Apoptosis	Cancer
HDAC6/HSP90-IN-2 (compound 6e) is a dual inhibitor of *HDAC6* and Hsp90, with IC₅₀s of 105.7 and 61 nM, respectively. HDAC6/HSP90-IN-2 can be used for the research of cancer.

HY-146293

HDAC6/HSP90-IN-1	HDAC HSP	Cancer
HDAC6/HSP90-IN-1 (compound 17) is a potent and selective dual inhibitor of *HDAC6* and HSP90, with IC₅₀ values of 4.3 and 46.8 nM, respectively. HDAC6/HSP90-IN-1 down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells. HDAC6/HSP90-IN-1 inhibits tumor growth in human H1975 xenograft mice.

HY-147730

HDAC6-IN-8	HDAC	Cancer
A variety of compounds were designed and synthesized by modifying cap groups. The enzyme inhibition test showed that compound 12C had broad-spectrum enzyme inhibitory activity, and compounds 9m and 9q were more inclined to inhibit HDAC6, showing a certain selective inhibitory activity among the representative subtypes.

HY-152133

*PROTAC HDAC6* degrader 1**	PROTACs HDAC Apoptosis	Cancer
PROTAC HDAC6 degrader (Compound A6) is a potent and selective PROTAC HDAC6 degrader with a DC₅₀ of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines.

HY-144449

*mTOR/HDAC6-IN-1*	mTOR HDAC Apoptosis Autophagy	Cancer
mTOR/HDAC6-IN-1 is a potent mTOR and *HDAC6* dual inhibitor (IC₅₀s of 133.7 nM and 56 nM for mTOR and HDAC6, respectively). mTOR/HDAC6-IN-1 can induce significant autophagy, apoptosis and suppress migration. mTOR/HDAC6-IN-1 has potential to research Triple-negative breast cancer (TNBC).

HY-131970

*LSD1/HDAC6-IN-1*	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6), with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM).

HY-16699

Nexturastat A	HDAC	Cancer
Nexturastat A is a potent, selective *HDAC6* inhibitor. Nexturastat A has inhibitory for HDAC6 with an IC₅₀ of 5 nM. Nexturastat A can be used for the research of multiple myeloma (MM).

HY-117554

BRD9757	HDAC	Cancer
BRD9757 is a potent, capless and selective *HDAC6* inhibitor with an IC₅₀ of 30 nM. BRD9757 shows excellent selectivity toward HDAC6 versus the class I (>20-fold) and class II (>400-fold) HDACs.

HY-128763

HDAC-IN-4
HDAC Cancer

HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor with pIC₅₀s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity.
HY-120448

QTX125
HDAC Apoptosis Cancer

QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.
HY-120448A

QTX125 TFA
HDAC Apoptosis Cancer

QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.
HY-146153

HDAC-IN-40
HDAC Cancer

HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with K_i values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects.

HDAC-IN-4	HDAC	Cancer
HDAC-IN-4 is a selective *HDAC6* and *HDAC10* inhibitor with pIC₅₀s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity.

QTX125	HDAC Apoptosis	Cancer
QTX125 is a potent and highly selective *HDAC6* inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.

QTX125 TFA	HDAC Apoptosis	Cancer
QTX125 TFA is a potent and highly selective *HDAC6* inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.

HDAC-IN-40	HDAC	Cancer
HDAC-IN-40 is a potent alkoxyamide-based *HDAC* inhibitor with K_i values of 60 nM and 30 nM for *HDAC2* and *HDAC6, respectively. HDAC*-IN-40 had antitumor effects.

HY-135890

CG347B	HDAC	Cancer Inflammation/Immunology Neurological Disease
CG347B is a selective *HDAC6* inhibitor, also involves in synthesis of other metalloenzyme inhibitors. *HDAC6* inhibitors can be used for oncology, immunology, and neurology research.

HY-18700

BRD73954	HDAC	Cancer
BRD73954 is a potent *HDAC* inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC₅₀ values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin.

HY-146160

*PARP-1/HDAC-IN-1*	PARP HDAC	Cancer
PARP-1/HDAC-IN-1 is a *PARP-1/HDAC6* dual targeting inhibitor with IC₅₀s of 68.90 nM and 510 nM, respectively. PARP-1/HDAC-IN-1 displays remarkable anticancer, anti-migration and anti-angiogenesis activities.

HY-114483

AES-135	HDAC	Cancer
AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC₅₀s ranging from 190-1100 nM.

HY-111791

ACY-1083	HDAC	Cancer
ACY-1083 is a selective and brain-penetrating *HDAC6* inhibitor with an IC₅₀ of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy.

HY-151569

SAHA-OH	HDAC Apoptosis	Inflammation/Immunology
SAHA-OH is a selective *HDAC6* inhibitor (IC₅₀=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis.

HY-150503

KH-259	HDAC	Neurological Disease
KH-259 (compound 1) is a potent, selective and CNS-penetrant *HDAC6* inhibitor, with an IC₅₀ of 0.26 μM. KH-259 has antidepressant effects in mice through the inhibition of HDAC6 in the brain. KH-259 can be used for neurodegenerative diseases research.

HY-15994

Citarinostat ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects.

HY-115475

SW-100	HDAC	Neurological Disease
SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier.

HY-19747

HPOB	HDAC Apoptosis	Cancer
HPOB is a highly potent and selective inhibitor of *HDAC6* with an IC₅₀ of 56 nM. HPOB displays >30 fold less potent against other HDACs. HPOB enhances the effectiveness of DNA-damaging anticancer agents in transformed cells but not normal cells. HPOB does not block the ubiquitin-binding activity of HDAC6.

HY-B0494

Bufexamac
Bufexamic acid
HDAC Inflammation/Immunology

Bufexamac is a class IIB histone deacetylases (HDAC6 and HDAC10) inhibitor used as an anti-inflammatory agent.

Bufexamac Bufexamic acid	HDAC	Inflammation/Immunology
Bufexamac is a class IIB histone deacetylases (HDAC6 and HDAC10) inhibitor used as an anti-inflammatory agent.

HY-13267

Droxinostat NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC).

HY-126147

J22352	HDAC	Cancer
J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective *HDAC6* inhibitor with an IC₅₀ value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1.

HY-19754A

CRA-026440 hydrochloride	HDAC Apoptosis	Cancer
CRA-026440 hydrochloride is a potent, broad-spectrum *HDAC* (HDAC) inhibitor. The K_i values against recombinant HDAC isoenzymes *HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10* are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities.

HY-126330

SS-208
HDAC Cancer

SS-208 is a selective HDAC6 inhibitor, with an IC₅₀ of 12 nM. SS-208 possesses anti-tumor activity in melanoma.

SS-208	HDAC	Cancer
SS-208 is a selective *HDAC6* inhibitor, with an IC₅₀ of 12 nM. SS-208 possesses anti-tumor activity in melanoma.

HY-133147

HDAC3/6-IN-2	HDAC Apoptosis	Cancer
HDAC3/6-IN-2 (compound 15) is a potent *HDAC6* and *HDAC3* inhibitor, with IC₅₀ values of 0.368 and 0.635 μM, respectively. HDAC3/6-IN-2 shows antitumor activity, and induces cancer cell apoptosis. HDAC3/6-IN-2 decreases the levels of *HDAC6* and *HDAC3*, associated with upregulation of acetylated H3 and α-tubulin.

HY-138799

KA2507	HDAC	Cancer
KA2507 is a potent, orally active and selective *HDAC6* inhibitor, with an IC₅₀ of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models.

HY-138799A

KA2507 monohydrochloride	HDAC	Cancer Inflammation/Immunology
KA2507 hydrochloride is a potent and highly selective inhibitor of *HDAC6* (IC₅₀=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects.

HY-152225

MC2625	HDAC Apoptosis	Cancer
MC2625 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2625 show selective HDAC3 and HDAC6 inhibition with IC₅₀s of 80 nM and 11 nM. MC2625 increases acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells (CSCs) growth by apoptosis induction.

HY-101780

Tinostamustine EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan *HDAC* inhibitor; inhibits *HDAC6, HDAC1, HDAC2* and *HDAC3* with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively.

HY-146539

HDAC-IN-35
HDAC VEGFR Cancer

HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively.

HY-123976A

MPT0G211 mesylate	HDAC	Cancer Neurological Disease
MPT0G211 mesylate is a potent, orally active and selective *HDAC6* inhibitor (IC₅₀=0.291 nM). MPT0G211 mesylate displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 mesylate can penetrate the blood-brain barrier. MPT0G211 mesylate ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 mesylate has anti-metastatic and neuroprotective effects. Anticancer activities.

HY-123976

MPT0G211	HDAC	Cancer Neurological Disease
MPT0G211 is a potent, orally active and selective *HDAC6* inhibitor (IC₅₀=0.291 nM). MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities.

HY-14718A

Resminostat hydrochloride RAS2410 hydrochloride; 4SC-201 hydrochloride	HDAC	Cancer
Resminostat hydrochloride is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-16026

Ricolinostat ACY-1215; Rocilinostat	HDAC Apoptosis	Cancer
Ricolinostat (ACY-1215) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits *HDAC1, HDAC2, and HDAC3* with IC₅₀s of 58, 48, and 51 nM, respectively.

HY-13428

Tubacin	HDAC Virus Protease	Cancer
Tubacin is a potent and selective inhibitor of *HDAC6, with an IC₅₀* value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-100871

WT-161	HDAC Apoptosis	Cancer
WT-161 is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 0.40 nM. WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-19327

ACY-738	HDAC	Cancer
ACY-738 is a potent, selective and orally-bioavailable *HDAC6* inhibitor, with an IC₅₀ of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC₅₀s of 94, 128, and 218 nM.

HY-111818

TH34
HDAC Cancer

TH34, an HDAC6/8/10 inhibitor with IC₅₀s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3.
HY-112908

RTS-V5
HDAC Proteasome Cancer

RTS-V5 is a dual HDAC/proteasome inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.
HY-132914

CDK/HDAC-IN-1
CDK Cancer

CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC₅₀ = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.

HY-150586

PTG-0861	HDAC Apoptosis	Cancer
PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC₅₀ value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers.

HY-143877

NN-390	HDAC	Cancer
NN-390 is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 9.8 nM. NN-390 penetrates the blood-brain barrier (BBB). NN-390 shows study potential in metastatic Group 3 MB (medulloblastoma).

HY-19328

ACY-775	HDAC	Neurological Disease Cardiovascular Disease
ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC₅₀ of 7.5 nM. ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-111400

SR-4370
HDAC Cancer

SR-4370 is an inhibitor of HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.

HY-18947

SKLB-23bb	HDAC	Cancer
SKLB-23bb is a potent and selective inhibitor for *HDAC6* with an IC₅₀ of 17 nM and shows 25-fold and 200-fold selectivity relative to *HDAC1* (IC₅₀=422 nM) and *HDAC8* (IC₅₀=3398 nM), respectively.

HY-14718

Resminostat RAS2410; 4SC-201	HDAC	Cancer
Resminostat (RAS2410; 4SC-201) is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-113957

MPI_5a	HDAC	Cancer
MPI_5a is a potent and selective *HDAC6* inhibitor (IC₅₀=36 nM). MPI_5a weakly inhibits other HDAC isoforms. MPI_5a inhibits acyl-tubulin accumulation in cells with an IC₅₀ value of 210 nM.

HY-153392

TYA-018	HDAC	Cardiovascular Disease
TYA-018 is an orally active, potent and highly selective *HDAC6* inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation.

HY-18712

BG45	HDAC Apoptosis Caspase	Cancer
BG45 is a potent *HDAC3* inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis.

HY-12954

PTACH NCH-51	HDAC HIV	Cancer Infection
PTACH (NCH-51) is a potent *HDAC* inhibitor with IC₅₀s of 48 nM, 32 nM, and 41 nM for *HDAC1, HDAC4, and HDAC6*, respectively. PTACH exerts potent growth inhibition against various cancer cells (EC₅₀s of 1.1-9.1 µM) .

HY-139181

NR160	HDAC	Cancer
NR160 is a selective HDAC6 inhibitor with an IC₅₀ value of 30 nM. NR160 shows low cytotoxicity against leukemia cell line. NR160 augments the apoptosis induction of Bortezomib (HY-10227) (proteasome inhibitor), Epirubicin (HY-13624) and Daunorubicin (HY-13062A) significantly.

HY-18613

CAY10603 BML-281	HDAC	Cancer
CAY10603 (BML-281) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.

HY-19754

CRA-026440	HDAC Apoptosis	Cancer Cardiovascular Disease
CRA-026440 is a potent, broad-spectrum *HDAC* inhibitor. The K_i values against recombinant HDAC isoenzymes *HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10* are 4, 14, 11, 15, 7, and 20 nM respectively. CRA-026440 shows antitumor and antiangiogenic activities.

HY-151897

HDAC-IN-49	HDAC	Cancer
HDAC-IN-49 is a potent unselective *HDAC* (HDAC) inhibitor with IC₅₀s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells.

HY-146684

HDAC-IN-36	HDAC Autophagy Apoptosis	Cancer
HDAC-IN-36 (compound 23 g) is an orally active and potent *HDAC* (histone deacetylase) inhibitor, with an IC₅₀ of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research.

HY-145687

HDAC-IN-32	HDAC	Cancer
HDAC-IN-32 is a potent *HDAC* inhibitor with IC₅₀s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity.

HY-18998

LMK-235	HDAC	Cancer
LMK-235 is a potent and selective *HDAC4/5* inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC₅₀s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

HY-145688

HDAC-IN-33	HDAC	Cancer
HDAC-IN-33 is a potent *HDAC* inhibitor with IC₅₀s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity.

HY-12164

Mocetinostat MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for *HDAC1, HDAC2, HDAC3* and *HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC*8.

HY-13271

Tubastatin A Hydrochloride Tubastatin A HCl; TSA HCl	HDAC Autophagy Apoptosis	Cancer
Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6* inhibitor* with IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-147892

HDAC-IN-42	HDAC Apoptosis	Cancer
HDAC-IN-42 (compound 14f) is a potent and selective *HDAC* inhibitor with IC₅₀ values of 0.19 and 4.98 µM for HDAC1 and HDAC6, respectively. HDAC-IN-42 shows anticancer and anti-proliferative activity. HDAC-IN-42 induces apoptosis and cell cycle arrest at G2/M phase.

HY-13271A

Tubastatin A	HDAC Autophagy Apoptosis	Cancer
Tubastatin A is a potent and selective HDAC6* inhibitor* with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-147873

*NMDAR/HDAC-IN-1*	iGluR HDAC	Neurological Disease
NMDAR/HDAC-IN-1 (Compound 9d) is a dual NMDAR and *HDAC* inhibitor with a K_i of 0.59 μM for NMDAR and IC₅₀ values of 2.67, 8.00, 2.21, 0.18 and 0.62 μM for HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8, respectively. NMDAR/HDAC-IN-1 efficiently penetrates the blood brain barrier.

HY-15149

Romidepsin FK 228; FR 901228; NSC 630176	HDAC Apoptosis	Cancer
Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis.

HY-115885

XP5	HDAC	Cancer Inflammation/Immunology
XP5 is a potent, orally active *HDAC6* inhibitor with an IC₅₀ of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma.

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target *HDAC* inhibitor, including *HDAC1* (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), *HDAC3* (IC₅₀=9.18 nM), *HDAC6* (IC₅₀=42.7 nM), *HDAC8* (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy.

HY-10221

Vorinostat SAHA; Suberoylanilide hydroxamic acid	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Cancer Infection
Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), *HDAC6* and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification.

HY-144332

PHD2/HDACs-IN-1	HDAC HIF/HIF Prolyl-Hydroxylase	Cancer
PHD2/HDACs-IN-1 is a potent *PHD2/HDACs* hybrid inhibitor (IC₅₀s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI).

HY-119939

CHDI-390576	HDAC	Cancer
CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC₅₀s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.

HY-146750

HDAC-IN-37	HDAC Apoptosis	Cancer
HDAC-IN-37 is a potent *HDAC* inhibitor with IC₅₀s of 0.0551 μM, 1.24 μM, 0.948 μM and 34.2 μM for *HDAC1, HDAC3, HDAC8* and *HDAC6, respectively. HDAC-IN-37 induces histone acetylation in a slow-off manner. HDAC-IN-37 prevents cell transition from G1 phase to S phase and induces early cell apoptosis*.

HY-138831

AES-350	HDAC Apoptosis	Cancer
AES-350 is a potent and orally active *HDAC6* inhibitor with an IC₅₀ and a K_i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC₅₀ values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research.

HY-143241

HDAC-IN-34	HDAC MDM-2/p53 Apoptosis	Cancer
HDAC-IN-34 (compound 27) is a potent *HDAC* inhibitor, with IC₅₀ values of 0.022 and 0.45 μM for *HDAC1* and *HDAC6, respectively. HDAC-IN-34 can bind to DNA and cause DNA damage. HDAC-IN-34 causes cells apoptosis* through p53 signaling pathway. HDAC-IN-34 exhibits significant anti-proliferation effect against HCT-116 cells, with an IC₅₀ of 1.41 μM.

HY-114414

HDACs/mTOR Inhibitor 1	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies.

HY-146159

*PI3K/HDAC-IN-2*	PI3K HDAC	Cancer
PI3K/HDAC-IN-2 is a potent dual *PI3K/HDAC* inhibitor with IC₅₀s of 226 nM, 279 nM, 467 nM, 29 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, respectively, and IC₅₀s of 1.3 nM, 3.4 nM, 972 nM, 17 nM, 12 nM for HDAC1, HDAC2, HDC4, HDAC6, HDAC8, respectively. PI3K/HDAC-IN-2 exhibits PI3Kδ and class I and IIb HDAC selectivity. PI3K/HDAC-IN-2 has remarkable anticancer effects.

HY-149029

TH-6	HDAC Apoptosis Reactive Oxygen Species	Cancer
TH-6 is a potent *HDAC* inhibitor with IC₅₀s of 0.115, 0.135, 0.242, 0.138, 2.120 µM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively. TH-6 inhibits cell migration and invasion. TH-6 induces apoptosis and cell cycle arrest at G2/M phase. TH-6 shows anti-tumor activity.

HY-124295

MPT0E028	HDAC Akt Apoptosis	Cancer
MPT0E028 is an orally active and selective *HDAC* inhibitor with IC₅₀s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity.

HY-130538

1-Naphthohydroxamic acid	HDAC	Cancer
1-Naphthohydroxamic acid (Compound 2) is a potent and selective *HDAC8* inhibitor with an IC₅₀ of 14 μM. 1-Naphthohydroxamic acid is more selectively for *HDAC8* than class I HDAC1 and class II HDAC6 (IC₅₀ >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity.1-Naphthohydroxamic acid can induce tubulin acetylation.

HY-114548

Ebselen oxide	Guanylate Cyclase	Infection
Ebselen oxide, the selenone analogue of Ebselen, covalently modifies diguanylate cyclase (DGC) to inhibit c-di-GMP-receptor interactions and reduces DGC activity. Ebselen oxide also inhibits alginate production (IC₅₀=14 μM) by Pseudomonas aeruginosa. Ebselen oxide inhibits HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 (IC₅₀ ranging from 0.2 to 4.7 μM).

HY-145851

*Top/HDAC-IN-1*	HDAC Topoisomerase Apoptosis	Cancer
Top/HDAC-IN-1 (Compound 29b) is a *topoisomerase/HDAC* dual inhibitor with IC₅₀s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC₅₀ of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells.

HY-144654

HDAC/Top-IN-1	HDAC Topoisomerase	Cancer
HDAC/Top-IN-1 is an orally active and pan *HDAC/Top* dual inhibitor with IC₅₀s of 0.036 μM, 0.14 μM, 0.059 μM, 0.089 μM and 9.8 μM for *HDAC1, HDAC2, HDAC3, HDAC6* and *HDAC8. HDAC/Top-IN-1 efficiently induces apoptosis* with S cell-cycle arrest in HEL cells. HDAC/Top-IN-1 has exhibits excellent in vivo antitumor efficacy.

HY-150597

HDAC-IN-46	HDAC Apoptosis	Cancer
HDAC-IN-46 (compound 12c) is a potent *HDAC* inhibitor with an IC₅₀ value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC).

HY-144725

HDAC1/6-IN-1	HDAC Apoptosis	Cancer
HDAC1/6-IN-1 (compound D7) is a potent multitarget inhibitor of GLP, *HDAC6* and *HDAC1, with IC₅₀* values of 1.3, 13, and 89 nM, respectively. HDAC1/6-IN-1 can inhibit the methylation and deacetylation of H3K9 on protein level. HDAC1/6-IN-1 induces cancer cell apoptosis, G0/G1 cell cycle arrest, and blocks migration and invasion.

HY-151153

HDAC1-IN-5	HDAC Microtubule/Tubulin Caspase Apoptosis	Cancer
HDAC1-IN-5 is a potent *HDAC1* inhibitor with IC₅₀ values of 15 nM and 20 nM for HDAC1 and HDAC6, respectively. HDAC1-IN-5 can enhance the acetylation of histone H3 and α-tubulin, as well as promote the activation of caspase 3 in cancer cells, thereby inducing apoptosis. HDAC1-IN-5 induces chromatin damage by binding with DNA. HDAC1-IN-5 has strong inhibitory activity against tumor growth in xenograft mice.

HY-110280

MC1742	HDAC Apoptosis	Cancer
MC1742 is a potent *HDAC* inhibitor, with IC₅₀s of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 and HDAC11, respectively. MC1742 can increase acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells growth. MC1742 can induce growth arrest, apoptosis, and differentiation in sarcoma CSC.

HY-146276

*CDK/HDAC-IN-2*	HDAC CDK Apoptosis	Cancer
CDK/HDAC-IN-2 is a potent *HDAC/CDK* dual inhibitor with IC₅₀ of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy.

HY-116818

Crebinostat	HDAC	Neurological Disease
Crebinostat is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.7 nM, 1.0 nM, 2.0 nM and 9.3 nM for HDAC1, HDAC2, HDAC3 and HDAC6, respectively. Crebinostat potently induces acetylation of both histone H3 and histone H4 as well as enhances the expression of the cAMP response element-binding protein (CREB) target gene Egr1. Crebinostat increases the density of synapsin-1 punctae along dendrites in cultured neurons. Crebinostat can modulate chromatin-mediated neuroplasticity and exhibits enhanced memory in mice.

HY-131708A

FNDR-20123	HDAC Parasite	Infection
FNDR-20123 is a safe, first-in-class, and orally active anti-malarial *HDAC* inhibitor with IC₅₀s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC₅₀=41 nM) and sexual blood stage (IC₅₀=190 nM for male gametocytes). FNDR-20123 inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC₅₀=25/29/2/11/282 nM, respectively.) and inhibits Class III HDAC isoforms at nanomolar concentrations.

HY-152146

HDAC-IN-50	Apoptosis FGFR HDAC	Cancer
HDAC-IN-50 is a potent and orally active FGFR and *HDAC* dual inhibitor with IC₅₀ values of 0.18, 1.2, 0.46, 1.4, 1.3, 1.6, 2.6, 13 nM for FGFR1, FGFR2, FGFR3, FGFR4, HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-50 induces Apoptosis and cell cycle arrest at G0/G1 phase. HDAC-IN-50 decreases the expression of pFGFR1, pERK, pSTAT3. HDAC-IN-50 shows anti-tumor activity.

HY-131708

FNDR-20123 free base	HDAC Parasite	Infection
FNDR-20123 free base is a safe, first-in-class, and orally active anti-malarial *HDAC* inhibitor with IC₅₀s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 free base exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC₅₀=41 nM) and sexual blood stage (IC₅₀=190 nM for male gametocytes). FNDR-20123 free base inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC₅₀=25, 29, 2, 11, and 282 nM, respectively) and inhibits Class III HDAC isoforms at nanomolar concentrations.

HY-143233

*PIM-1/HDAC-IN-1*	Pim HDAC Apoptosis	Cancer
PIM-1/HDAC-IN-1 (compound 4d) is a PIM-1 inhibitor, with an IC₅₀ of 343.87 nM. PIM-1/HDAC-IN-1 has strong inhibitory activity and selectivity against HDAC 1 and *HDAC 6, with IC₅₀* values of 63.65 and 62.39 nM, respectively. PIM-1/HDAC-IN-1 exhibits apoptosis inducing potential in MCF-7 cell lines. PIM-1/HDAC-IN-1 shows pre-G1 apoptosis and cell cycle arrest at G2/M phase.

HY-149283

*JAK/HDAC-IN-2*	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine *JAK/HDAC* dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers.

HY-152226

MC2590	HDAC Apoptosis	Cancer
MC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC₅₀s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC₅₀s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction.

Cat. No.	Product Name	Target	Research Area

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target *HDAC* inhibitor, including *HDAC1* (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), *HDAC3* (IC₅₀=9.18 nM), *HDAC6* (IC₅₀=42.7 nM), *HDAC8* (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy.

Species:	Human (2)
Tag:	SUMO (1) His (2)
Source:	E. coli (2)

Cat. No.	Product Name	Species	Source

HY-P72223

HDAC6 Protein, Human (His-SUMO) CPBHM; FLJ16239; HD 6; HD6; HDAC 6; HDAC6; HDAC6_HUMAN; Histone deacetylase 6 HD6; ; Histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90	Human	E. coli

HY-P72224

HDAC6 Protein, Human (His) CPBHM; FLJ16239; HD 6; HD6; HDAC 6; HDAC6; HDAC6_HUMAN; Histone deacetylase 6 HD6; ; Histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90	Human	E. coli

Cat. No.	Product Name	Application	Reactivity

HY-P80154

HDAC6 Antibody	WB, ICC/IF, IHC-P, IP	Human
HDAC6 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to HDAC6. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human.

HY-P80701

HDAC6 Antibody (YA740) HDAC6; KIAA0901; JM21; Histone deacetylase 6; HD6	WB	Human, Rat
HDAC6 Antibody (YA740) is a non-conjugated and Mouse origined monoclonal antibody about 131 kDa, targeting to HDAC6 (3B2). It can be used for WB assays with tag free, in the background of Human, Rat.